JP2023538129A5 - - Google Patents

Info

Publication number
JP2023538129A5
JP2023538129A5 JP2023512697A JP2023512697A JP2023538129A5 JP 2023538129 A5 JP2023538129 A5 JP 2023538129A5 JP 2023512697 A JP2023512697 A JP 2023512697A JP 2023512697 A JP2023512697 A JP 2023512697A JP 2023538129 A5 JP2023538129 A5 JP 2023538129A5
Authority
JP
Japan
Prior art keywords
amino acid
acid selected
aav capsid
seq
furthermore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538129A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046904 external-priority patent/WO2022040527A2/en
Publication of JP2023538129A publication Critical patent/JP2023538129A/ja
Publication of JP2023538129A5 publication Critical patent/JP2023538129A5/ja
Pending legal-status Critical Current

Links

JP2023512697A 2020-08-21 2021-08-20 好ましい発現レベルを有するアデノ随伴ウイルス組成物 Pending JP2023538129A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068614P 2020-08-21 2020-08-21
US63/068,614 2020-08-21
PCT/US2021/046904 WO2022040527A2 (en) 2020-08-21 2021-08-20 Adeno-associated virus compositions having preferred expression levels

Publications (2)

Publication Number Publication Date
JP2023538129A JP2023538129A (ja) 2023-09-06
JP2023538129A5 true JP2023538129A5 (cg-RX-API-DMAC7.html) 2024-08-28

Family

ID=80323313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512697A Pending JP2023538129A (ja) 2020-08-21 2021-08-20 好ましい発現レベルを有するアデノ随伴ウイルス組成物

Country Status (7)

Country Link
US (1) US20230303630A1 (cg-RX-API-DMAC7.html)
EP (1) EP4199972A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023538129A (cg-RX-API-DMAC7.html)
CN (1) CN117321213A (cg-RX-API-DMAC7.html)
AU (1) AU2021329527A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192600A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022040527A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
EP4322976A4 (en) * 2021-04-13 2025-06-25 Capsida, Inc. AAV COMPOSITIONS WITH HIGH EXPRESSION LEVELS IN THE BRAIN
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
EP4426716A1 (en) 2021-11-02 2024-09-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
CN119095867A (zh) * 2022-03-24 2024-12-06 卡西达公司 具有优选的脑富集的所选aav组合物
CN114774373B (zh) * 2022-04-27 2024-07-05 北京市农林科学院 信鸽新城疫病毒基因工程改造弱毒株及其制备方法和应用
EP4269426A1 (en) * 2022-04-29 2023-11-01 Ospedale San Raffaele S.r.l. Gene therapy
WO2023215546A2 (en) * 2022-05-06 2023-11-09 Capsida, Inc. Adeno-associated virus compositions having increased brain enrichment
EP4526325A4 (en) * 2022-05-17 2026-08-05 Capsida Inc SELECTED ADENE-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED LEVELS OF CEREBRAL, SPINAL CORD AND/OR CARDIAC EXPRESSION
WO2023244919A1 (en) * 2022-06-16 2023-12-21 Capsida, Inc. Adeno-associated virus compositions having increased brain enrichment and decreased liver enrichment
AU2023363990A1 (en) * 2022-10-19 2025-05-08 Capsida Biotherapeutics, Inc. Adeno-associated virus compositions having preferred brain enrichment and low liver enrichment
AU2023364350A1 (en) 2022-10-19 2025-06-05 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
JP2026509271A (ja) 2023-03-10 2026-03-17 ダイノ セラピューティクス,インコーポレーテッド カプシドポリペプチドおよびその使用方法
CN120660140A (zh) * 2023-03-27 2025-09-16 浙江大学 氨基酸序列的生成与筛选方法及其系统
KR20260045798A (ko) * 2023-06-30 2026-04-03 캡시다 바이오테라퓨틱스, 인크. 증가된 뇌 풍부화를 갖는 아데노-연관 바이러스 조성물
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025213066A1 (en) * 2024-04-05 2025-10-09 Capsida Biotherapeutics, Inc. Adeno-associated virus compositions for treating parkinson's disease (pd)
WO2025231383A1 (en) * 2024-05-03 2025-11-06 Capsida Biotherapeutics, Inc. Compositions and methods of delivering a therapeutic across the blood-brain barrier via the pl16 receptor
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710036B2 (en) * 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
DK3693025T3 (da) * 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
DE102014207498A1 (de) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
CN109640949B (zh) * 2016-07-29 2022-11-25 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体和其使用方法
JP2021530218A (ja) * 2018-07-11 2021-11-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 血液脳関門を超える薬剤の送達のための方法および組成物
EP3830107A2 (en) * 2018-08-03 2021-06-09 Voyager Therapeutics, Inc. Aav variants with enhanced tropism
US11149256B2 (en) * 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
US12281321B2 (en) * 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN113166208B (zh) * 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性

Similar Documents

Publication Publication Date Title
JP2024513949A5 (cg-RX-API-DMAC7.html)
EP1828390B1 (en) Chimeric vectors
JP6387350B2 (ja) 希突起神経膠細胞を標的とするアデノ随伴ウイルスベクター
JP7624724B2 (ja) 標的遺伝子療法のためのアデノ随伴ウイルス組成物
JP2022526018A5 (cg-RX-API-DMAC7.html)
ES2340230T3 (es) Vectores viricos y sus procedimientos de preparacion y administracion.
US7867484B2 (en) Heparin and heparan sulfate binding chimeric vectors
JP2025179046A5 (cg-RX-API-DMAC7.html)
JP6309373B2 (ja) Aavベクターの末梢注入を使用する広範囲におよぶ運動ニューロンへの遺伝子の送達
JP2021516044A (ja) 抗体回避ウイルスベクターのための方法および組成物
US20020192823A1 (en) AAV2 vectors and methods
JP2023551903A5 (cg-RX-API-DMAC7.html)
JP2024510757A5 (cg-RX-API-DMAC7.html)
JP2020533968A (ja) 組換えアデノ随伴ベクター
JP7490632B2 (ja) Cd4ムテインおよびその使用方法
JP2022519597A5 (cg-RX-API-DMAC7.html)
CA3199756A1 (en) Adeno-associated virus vectors
US20250325703A1 (en) Composition for delivering gene to brain tissue and use thereof
JP2025510946A5 (cg-RX-API-DMAC7.html)
WO2022150409A1 (en) Treatments for intraocular pressure related disorders
DK2579885T3 (en) Parvovirus for the treatment of tumors by intranasal use.
JP2023545384A5 (cg-RX-API-DMAC7.html)
JP2023536067A (ja) 最適化されたslc13a5遺伝子および発現カセットならびにそれらの使用
JP2023536067A5 (cg-RX-API-DMAC7.html)
AU2020216501A1 (en) One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation